Edition:
United Kingdom

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

10.68USD
20 Nov 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$10.68
Open
$10.36
Day's High
$11.15
Day's Low
$10.18
Volume
43,881
Avg. Vol
76,716
52-wk High
$37.00
52-wk Low
$5.47

Latest Key Developments (Source: Significant Developments)

Catalyst Biosciences Reports Q3 Loss Per Share $0.64
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES REPORTS THIRD QUARTER OPERATING & FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE.Q3 LOSS PER SHARE $0.64.ENDED Q3 WITH CASH BALANCE OF ABOUT $129M.  Full Article

Catalyst Biosciences Q2 Loss Per Share $0.54
Thursday, 2 Aug 2018 

Catalyst Biosciences Inc ::CATALYST BIOSCIENCES REPORTS SECOND QUARTER OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.54.Q2 EARNINGS PER SHARE VIEW $-0.62 -- THOMSON REUTERS I/B/E/S.  Full Article

Catalyst Biosciences Receives $1.5 Million For Neuronal Nicotinic Receptor Asset
Monday, 26 Mar 2018 

March 26 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES RECEIVES $1.5 MILLION IN TWO MILESTONE PAYMENTS FOR NEURONAL NICOTINIC RECEPTOR (NNR) ASSET.  Full Article

Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences
Wednesday, 27 Dec 2017 

Dec 28 (Reuters) - Catalyst Biosciences Inc ::NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING.  Full Article

Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES INC - ‍PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.1 MILLION SHARES OF COMMON STOCK, OFFERED AT A PRICE OF $9.50 PER SHARE TO PUBLIC​.  Full Article

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES INC - ANTICIPATES USING PROCEEDS FROM OFFERING FOR CLINICAL TRIALS, RESEARCH AND DEVELOPMENT ACTIVITIES, CAPEX.  Full Article

Catalyst Biosciences Appoints Edward Williams To Its Board
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES APPOINTMENT OF EDWARD WILLIAMS TO ITS BOARD OF DIRECTORS.CATALYST BIOSCIENCES INC - BARRY SELICK, WHO HAS BEEN CHAIRMAN SINCE 2006, WILL STEP DOWN FROM BOARD EFFECTIVE FEB. 15, 2018.CATALYST BIOSCIENCES INC - ‍CURRENT BOARD MEMBER AUGUSTINE LAWLOR WILL REPLACE SELICK AS CHAIRMAN​.  Full Article

Catalyst biosciences Q3 loss per share $1.34
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Catalyst Biosciences Inc :Catalyst Biosciences reports third quarter 2017 operating & financial results and provides corporate update.Q3 loss per share $1.34.Catalyst Biosciences Inc - ‍phase 1/2 trial of factor IX CB 2679D is advancing with interim results expected by year-end​.Catalyst Biosciences Inc - ‍phase 2 trial of factor Fviia Marzeptacog Alfa (activated) on track for initiation by year-end​.Catalyst Biosciences- ‍believes existing capital resources will be sufficient to meet its projected operating requirements for at least next 12 months​.  Full Article

Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Catalyst Biosciences Inc ::Catalyst Biosciences and Mosaic Biosciences enter into strategic collaboration to develop intravitreal anti-complement factor 3 (c3) products for the treatment of dry amd and other retinal diseases.Catalyst Biosciences - ‍under terms of agreement, co, mosaic will collaborate to improve pharmacokinetic (pk) properties of co's anti-c3 proteases​.Catalyst Biosciences Inc - ‍will retain global commercial rights for all collaboration products​.Catalyst Biosciences Inc - ‍for all collaboration products, mosaic will receive product sublicense fees and/or milestone payments and royalties​.  Full Article